SAN DIEGO--(BUSINESS WIRE)--
Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and
manufacturer of the only touchscreen insulin pumps available in the
United States, today announced that it has filed a registration
statement on Form S-1 with the Securities and Exchange Commission
relating to a proposed follow-on public offering of approximately $50
million of its common stock. All of the shares to be sold in the
offering will be offered by Tandem. In addition, Tandem expects to grant
to the underwriters a 30-day option to purchase up to approximately $7.5
million of additional common stock. The number of shares to be offered
and the price for the proposed offering have not yet been determined.
The offering will be subject to market conditions and other factors and
there can be no assurance as to whether or when the offering may be
completed, or as to the actual size or terms of the offering.
Piper Jaffray & Co. is acting as the sole book-running manager for the
offering. Wedbush PacGrow is acting as a co-manager.
A registration statement relating to the securities has been filed with
the Securities and Exchange Commission, but has not yet become
effective. The securities may not be sold, nor may offers to buy the
securities be accepted, prior to the time the registration statement
becomes effective. The offering will be made only by means of a
prospectus that forms a part of the registration statement. When
available, copies of the prospectus relating to the offering may be
obtained from: Piper Jaffray & Co. at 800 Nicollet Mall, J12S03,
Minneapolis, MN 55402, Attention: Prospectus Department, or by calling
800-747-3924, or by emailing prospectus@pjc.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc.
is a medical device company with an innovative, user-centric and
integrated approach to the design, development and commercialization of
products for people with diabetes who use insulin. The Company
manufactures and sells the t:slim X2™ Insulin Pump, the slimmest and
smallest durable insulin pump currently on the market, the t:flex®
Insulin Pump, the first pump designed for people with greater insulin
requirements, and the t:slim G4™ Insulin Pump, the first continuous
glucose monitoring-enabled pump with touchscreen simplicity. Tandem is
based in San Diego, California.
t:flex and Tandem Diabetes Care are registered trademarks, and t:slim X2
and t:slim G4 are trademarks of Tandem Diabetes Care, Inc.
Forward Looking Statement
This press release contains
"forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended, that concern matters that involve
risks and uncertainties that could cause actual results to differ
materially from those anticipated or projected in the forward-looking
statements. These forward-looking statements include statements
regarding the proposed follow-on public offering, including the
anticipated amount to be raised in the offering. The Company's actual
results, and the timing of events, could differ materially from those
indicated in these forward-looking statements due to numerous risks and
uncertainties, including market conditions at the time the Company
conducts the proposed offering, the reaction of investors to the
Company's recently announced financial condition, results of operations
and liquidity position, and the Company's ability to satisfy closing
conditions related to the proposed offering. In addition, our results
may be impacted by the other risks identified in the Company's
Registration Statement on Form S-1 relating to the offering, and other
documents that the Company files with the Securities and Exchange
Commission. Investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
release. Unless otherwise required by applicable law or the rules of the
NASDAQ Stock Market, Tandem undertakes no obligation to update or review
any forward-looking statement in this press release because of new
information, future events or other factors.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170308006285/en/
Tandem Diabetes Care, Inc.
Susan Morrison
858-366-6900 x7005
smorrison@tandemdiabetes.com
Source: Tandem Diabetes Care®, Inc.
News Provided by Acquire Media
